Targeting Glucose Metabolism Enzymes in Cancer Treatment: Current and Emerging Strategies
Open accessThe DOI matches its Crossref record; 316 of the 322 references it cites were found in a registry or an index.
Abstract
Reprogramming of glucose metabolism provides sufficient energy and raw materials for the proliferation, metastasis, and immune escape of cancer cells, which is enabled by glucose metabolism-related enzymes that are abundantly expressed in a broad range of cancers. Therefore, targeting glucose metabolism enzymes has emerged as a promising strategy for anticancer drug development. Although several glucose metabolism modulators have been approved for cancer treatment in recent years, some limitations exist, such as a short half-life, poor solubility, and numerous adverse effects. With the rapid development of medicinal chemicals, more advanced and effective glucose metabolism enzyme-targeted anticancer drugs have been developed. Additionally, several studies have found that some natural products can suppress cancer progression by regulating glucose metabolism enzymes. In this review, we summarize the mechanisms underlying the reprogramming of glucose metabolism and present enzymes that could serve as therapeutic targets. In addition, we systematically review the existing drugs targeting glucose metabolism enzymes, including small-molecule modulators and natural products. Finally, the opportunities and challenges for glucose metabolism enzyme-targeted anticancer drugs are also discussed. In conclusion, combining glucose metabolism modulators with conventional anticancer drugs may be a promising cancer treatment strategy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“While many of these have shown efficacy in pre-clinical models, challenges in achieving selectivity, combined with pathway redundancies and bypass mechanisms may limit their utility as single agents in the clinic [55].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [55]
The cited source says what the claim attributes to it.
In the citing paper
“Similarly, anti-cancer agents that target the multiple steps of glucose metabolism from glucose uptake to lactate production have also been developed (Table 2) [55].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [55]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–316 of 316
Nath, K., Nelson, D. S., Heitjan, D. F., Leeper, D. B., Zhou, R., & Glickson, J. D. (2015) · NMR in Biomedicine · doi:10.1002/nbm.3240 · Cited by 80
p63 supports aerobic respiration through hexokinase II
Viticchiè, G., Agostini, M., Lena, A. M., Mancini, M., Zhou, H., Zolla, L., Dinsdale, D., Saintigny, G., Melino, G., & Candi, E. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1508871112 · Cited by 80
Seyfried, T. N., Marsh, J., Shelton, L. M., Huysentruyt, L. C., & Mukherjee, P. (2011) · Epilepsy Research · doi:10.1016/j.eplepsyres.2011.06.017 · Cited by 80
Liu, J., Wu, N., Ma, L., Liu, M., Liu, G., Zhang, Y., & Lin, X. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091606 · Cited by 79
Self-citationGrandjean, G., de Jong, P. R., James, B. P., Koh, M. Y., Lemos, R., Kingston, J., Aleshin, A., Bankston, L. A., Miller, C. P., Cho, E. J., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0401 · Cited by 78
Advances in Understanding the Role of Aloe Emodin and Targeted Drug Delivery Systems in Cancer
Karatoprak, G. Ş., Akkol, E. K., Yücel, Ç., Açıkara, Ö. B., & Sobarzo‐Sánchez, E. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/7928200 · Cited by 77
Wu, J., Zhang, X., Wang, Y., Sun, Q., Chen, M., Liu, S., & Zou, X. (2017) · Oncology Reports · doi:10.3892/or.2017.6155 · Cited by 75
Wang, Y., Qu, C., Liu, T., & Wang, C. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112612 · Cited by 75
Chen, G., Tang, C., Shi, X., Lin, C., Fatima, S., Pan, X., Yang, D., Zhang, G., Lü, A., Lin, S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4376 · Cited by 73
Ketoconazole and Posaconazole Selectively Target HK2-expressing Glioblastoma Cells
Agnihotri, S., Mansouri, S., Burrell, K., Li, M., Mamatjan, Y., Liu, J., Nejad, R., Kumar, S., Jalali, S., Singh, S. K., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1854 · Cited by 73
Apigenin and hesperidin augment the toxic effect of doxorubicin against HepG2 cells
Korga-Plewko, A., Ostrowska-Leśko, M., Józefczyk, A., Iwan, M., Wojcik, R., Zgórka, G., Herbet, M., Vilarrubla, G. G., & Dudka, J. (2019) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-019-0301-2 · Cited by 73
The development of small-molecule inhibitors targeting hexokinase 2
Shan, W., Zhou, Y., & Tam, K. Y. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.05.017 · Cited by 73
George Thompson, A. M., Iancu, C. V., Nguyen, T. T. H., Kim, D., & Choe, J.-Y. (2015) · Scientific Reports · doi:10.1038/srep12804 · Cited by 72
Oxamate targeting aggressive cancers with special emphasis to brain tumors
Altinoz, M. A., & Özpınar, A. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112686 · Cited by 72
Curcumin directly inhibits the transport activity of GLUT1
Gunnink, L. K., Alabi, O. D., Kuiper, B. D., Gunnink, S. M., Schuiteman, S. J., Rylaarsdam, L. E., Hamilton, K. E., Wrobel, K. E., & Louters, L. L. (2016) · Biochimie · doi:10.1016/j.biochi.2016.03.014 · Cited by 70 · cited 1×
“In addition, natural products such as trehalose (Figure 3K) [78], silibinin (Figure 3L) [79], curcumin (Figure 3M) [80], resveratrol (Figure 3N) [81], naringenin [82], quercetin [83], isoquercetin [84], kaempferol [85], xanthohumol [86], caffeine [87], bezielle [88], theophylline [89], (+)-Cryptocaryone [90], and mela…”
BackgroundmTOR up-regulation of PFKFB3 is essential for acute myeloid leukemia cell survival
Feng, Y., & Wu, L.-S. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.01.031 · Cited by 70
A targeted nanomodulator capable of manipulating tumor microenvironment against metastasis
Tian, H., Zhou, L., Wang, Y., Nice, E. C., Huang, C., & Zhang, H. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.06.022 · Cited by 70
Self-citationZhang, Q., Liu, Q., Zheng, S., Liu, T., Yang, L., Han, X., & Lu, X. (2021) · Journal of Cancer · doi:10.7150/jca.58494 · Cited by 69
Shang, D., Ju, W., Guo, L., Yan-ju, X., Liu, L., & Lu, J. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.3950 · Cited by 68
Upregulation of the ALDOA/DNA-PK/p53 pathway by dietary restriction suppresses tumor growth
Ma, D., Chen, X., Zhang, P.-Y., Zhang, H., Wei, L.-J., Hu, S., Tang, J.-Z., Zhou, M.-T., Xie, C., Ou, R., et al. (2017) · Oncogene · doi:10.1038/onc.2017.398 · Cited by 68
Self-citationNindawat, S., & Agrawal, V. (2019) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2018.1548469 · Cited by 67
McDonnell, S. R. P., Hwang, S. R., Rolland, D. C. M., Murga‐Zamalloa, C., Basrur, V., Conlon, K. P., Fermin, D., Wolfe, T., Raskind, A. B., Ruan, C., et al. (2013) · Blood · doi:10.1182/blood-2013-01-482026 · Cited by 66
Zhao, H., Han, L., Jian, Y., Ma, Y., Yan, W., Chen, X., Xu, H., & Li, L. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s186247 · Cited by 65
Akt inhibition promotes hexokinase 2 redistribution and glucose uptake in cancer cells
Neary, C. L., & Pastorino, J. G. (2013) · Journal of Cellular Physiology · doi:10.1002/jcp.24361 · Cited by 64
Glucose metabolic phenotype of pancreatic cancer
Chan, A. K. C., Bruce, J. I. E., & Siriwardena, A. K. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i12.3471 · Cited by 64
Pharmacokinetics and toxicity of oral and intravenous lonidamine in dogs
Price, G. S., Page, R. L., Riviere, J. E., Cline, J. M., & Thrall, D. Ε. (1996) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050460 · Cited by 62
Vitamin K3 and K5 are inhibitors of tumor pyruvate kinase M2
Chen, J., Jiang, Z., Wang, B., Wang, Y., & Hu, X. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.10.039 · Cited by 61
The role of pyruvate kinase M2 in anticancer therapeutic treatments (Review)
Su, Q., Luo, S., Tan, Q., Deng, J., Zhou, S., Peng, M., Tao, T., & Yang, X. (2019) · Oncology Letters · doi:10.3892/ol.2019.10948 · Cited by 61
Insights into the New Cancer Therapy through Redox Homeostasis and Metabolic Shifts
Hyun, D. (2020) · Cancers · doi:10.3390/cancers12071822 · Cited by 61 · cited 1×
“In addition, natural products such as trehalose (Figure 3K) [78], silibinin (Figure 3L) [79], curcumin (Figure 3M) [80], resveratrol (Figure 3N) [81], naringenin [82], quercetin [83], isoquercetin [84], kaempferol [85], xanthohumol [86], caffeine [87], bezielle [88], theophylline [89], (+)-Cryptocaryone [90], and mela…”
BackgroundYu, H., Yin, Y., Yi, Y., Cheng, Z., Kuang, W., Li, R., Zhong, H., Cui, Y., Yuan, L., Gong, F., et al. (2020) · 癌症:英文版 · doi:10.1002/cac2.12080 · Cited by 60
Proteomics identification of PGAM1 as a potential therapeutic target for urothelial bladder cancer
Peng, X., Gong, F. M., Chen, Y., Qiu, M., Cheng, K., Tang, J., Ge, J., Chen, N., Zeng, H., & Liu, J. Y. (2015) · Journal of Proteomics · doi:10.1016/j.jprot.2015.11.027 · Cited by 59
Ding, Y., Xue, Q., Liu, S., Hu, K., Wang, D., Wang, T., Li, Y., Guo, H., Hao, X., Ge, W., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01328 · Cited by 58
Self-citationDevelopment of GLUT4-selective antagonists for multiple myeloma therapy
Wei, C., Bajpai, R., Sharma, H., Heitmeier, M. R., Jain, A. D., Matulis, S. M., Nooka, A. K., Mishra, R. K., Hruz, P. W., Schiltz, G. E., et al. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.08.029 · Cited by 57 · cited 1×
“Multiple myeloma mainly expresses GLUT4, which is responsible for maintaining adequate glucose uptake [33,38].”
BackgroundLiu, M., Zhang, Z., Wang, H., Chen, X., & Jin, C. (2019) · International Journal of Biological Sciences · doi:10.7150/ijbs.29689 · Cited by 57
Guo, Y., Wei, L., Zhou, Y., Lu, N., Tang, X., Li, Z., & Wang, X. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2019.10.413 · Cited by 57
Self-citationYan, S., Zhou, N., Zhang, D., Zhang, K., Zheng, W., Bao, Y., & Yang, W. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215415 · Cited by 57
Tyagi, K., Mandal, S., & Roy, A. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188563 · Cited by 57
Identification of novel GLUT inhibitors
Siebeneicher, H., Bauser, M., Buchmann, B., Heisler, I., Müller, T., Neuhaus, R., Rehwinkel, H., Telser, J., & Zorn, L. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.02.050 · Cited by 56 · cited 2×
“esters [60], pyrazolo-pyrimidines [37], quinazolines [61], phenylalanine amides [62] and many more [35,58,63–67], EF24 [59], ketoximes [36], polyphenolic esters [60], pyrazolopyrimidines [37], quinazolines [61], phenylalanine amides [62], and many more [63–67], have emerged but need to be more deeply investigated.”
BackgroundBlocking LDHA glycolytic pathway sensitizes glioblastoma cells to radiation and temozolomide
Koukourakis, M. I., Tsolou, A., Pouliliou, S., Lamprou, I., Papadopoulou, M., Ilemosoglou, M., Kostoglou, G., Ananiadou, D., Sivridis, E., & Giatromanolaki, A. N. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.07.138 · Cited by 55
Epigallocatechin gallate inhibits human tongue carcinoma cells via HK2-mediated glycolysis
Gao, F., Li, M., Liu, W., ZHOU, Z.-S., Zhang, R., LI, J.-L., & Zhou, K. (2015) · Oncology Reports · doi:10.3892/or.2015.3727 · Cited by 54
Inhibitor Discovery for the Human GLUT1 from Homology Modeling and Virtual Screening
Ung, P. M.-U., Song, W., Cheng, L., Zhao, X., Hu, H., Chen, L., & Schlessinger, A. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00304 · Cited by 54 · cited 2×
“With the advancement of technology, novel GLUT inhibitors, such as PUG-1 (Figure 3E) [54], chromopynones (Figure 3F) [55–57], rapaglutin A [35,58], EF24 [59], ketoximes [36], polyphenolic”
BackgroundTao, L., Wei, L., Liu, Y., Ding, Y., Liu, X., Zhang, X., Wang, X., Yao, Y., Lu, J., Wang, Q., et al. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.11.001 · Cited by 54
Self-citationZhang, J., Chen, L., Wei, Z., Yang, W., Ge, W., Qu, X., Si, W., Wang, W., Mou, X., & Dong, X. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121682 · Cited by 53
Amadori, D., Frassineti, G. L., Matteis, A. D., Mustacchi, G., Santoro, A., Cariello, S., Ferrari, M., Nascimben, O., Nanni, O., Lombardi, A., et al. (1998) · Breast Cancer Research and Treatment · doi:10.1023/a:1006063412726 · Cited by 52
In vitro effects of some flavonoids and phenolic acids on human pyruvate kinase isoenzyme M2
Aslan, E., Güler, Ç., & Adem, Ş. (2015) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.3109/14756366.2015.1022173 · Cited by 52
ENO1 Overexpression in Pancreatic Cancer Patients and Its Clinical and Diagnostic Significance
Yin, H., Wang, L., & Liu, H. (2018) · Gastroenterology Research and Practice · doi:10.1155/2018/3842198 · Cited by 52
Discovery of a Potent GLUT Inhibitor from a Library of Rapafucins by Using 3D Microarrays
Guo, Z., Cheng, Z., Wang, J., Liu, W., Peng, H., Wang, Y., Rao, A., Li, R., Ying, X., Korangath, P. C., et al. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201905578 · Cited by 51
Li, X., Jiang, F., Zhong, G., Chen, B., Yu, J., Xin, M.-J., Wang, J., An, L., Wei, J., & Wu, L. (2019) · Digestive Diseases and Sciences · doi:10.1007/s10620-019-05642-2 · Cited by 50
Zhang, Y., Liu, B., Wu, X., Li, R., Ning, X., Liu, Y., Liu, Z., Ge, Z., Li, R., & Yin, Y. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.05.041 · Cited by 49
Self-citationTang, J., Zhao, J., Long, F., Chen, J., Mu, B., Jiang, Z., Ren, Y., & Yang, J. (2017) · Journal of Cancer · doi:10.7150/jca.21224 · Cited by 47
Lapa, B., Gonçalves, A. C., Jorge, J., Alves, R., Pires, A. S., Abrantes, A. M., Coucelo, M., Abrunhosa, A., Botelho, M. F., Costa, N., et al. (2020) · Medical Oncology · doi:10.1007/s12032-020-01394-6 · Cited by 47
Han, J., Meng, Q., Xi, Q., Wang, H., & Wu, G. (2016) · Cancer Biomarkers · doi:10.3233/cbm-160143 · Cited by 46
Wubben, T. J., Pawar, M. D., Weh, E., Smith, A. J. H., Sajjakulnukit, P., Zhang, L., Dai, L., Hager, H. M., Pai, M. P., Lyssiotis, C. A., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-59999-w · Cited by 46
Overexpression of PFKFB3 promotes cell glycolysis and proliferation in renal cell carcinoma
Li, J., Zhang, S., Liao, D., Zhang, Q., Chen, C., Yang, X., Jiang, D., & Pang, J. (2022) · BMC Cancer · doi:10.1186/s12885-022-09183-2 · Cited by 45
Kontogiannopoulos, K. N., Assimopoulou, A. N., Hatziantoniou, S., Karatasos, K., Demetzos, C., & Papageorgiou, V. P. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.09.031 · Cited by 44
Lea, M. A., Guzman, Y., & desBordes, C. (2016) · PubMed · Cited by 44
Muramatsu, H., Sumitomo, M., Morinaga, S., Kajikawa, K., Kobayashi, I., Nishikawa, G., Kato, Y., Watanabe, M., Zennami, K., Kanao, K., et al. (2019) · Oncology Reports · doi:10.3892/or.2019.7171 · Cited by 44
Brooke, D. G., van Dam, E. M., Watts, C. K. W., Khoury, A., Dziadek, M. A., Brooks, H., Graham, L.-J. K., Flanagan, J. U., & Denny, W. A. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.12.041 · Cited by 41
Wang, H., Zhu, Z., Zhang, G., Lin, F., Liu, Y., Zhang, Y., Feng, J., Chen, W., Meng, Q., & Chen, L. (2019) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.08.017 · Cited by 41
Self-citationZhang, D., Wang, Y., Dong, L., Huang, Y., Yuan, J., Ben, W., Yang, Y., Ning, N., Lu, M., & Guan, Y. (2013) · Cancer Science · doi:10.1111/cas.12293 · Cited by 40
Fang, J., Bao, Y.-Y., Zhou, S.-H., & Fan, J. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.4233 · Cited by 40
Tilekar, K. N., Upadhyay, N., Schweipert, M., Hess, J. D., Macias, L. G.-F., Mrówka, P., Meyer‐Almes, F., Aguilera, R. J., Iancu, C. V., Choe, J., et al. (2020) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2020.105512 · Cited by 40
Targeting glucose metabolism to develop anticancer treatments and therapeutic patents
Zhou, Y., Guo, Y., & Tam, K. Y. (2022) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2022.2027912 · Cited by 40
Liu, S., Yan, B., Lai, W., Chen, L., Xiao, D., Xi, S., Jiang, Y., Dong, X., An, J., Chen, X., et al. (2014) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2014.05.017 · Cited by 39
Ren, Y.-L., Yuan, C., Qian, Y., Chai, H., Chen, X.-Z., Goetz, M., & Kinghorn, A. (2013) · Journal of Natural Products · doi:10.1021/np400809w · Cited by 39 · cited 1×
“In addition, natural products such as trehalose (Figure 3K) [78], silibinin (Figure 3L) [79], curcumin (Figure 3M) [80], resveratrol (Figure 3N) [81], naringenin [82], quercetin [83], isoquercetin [84], kaempferol [85], xanthohumol [86], caffeine [87], bezielle [88], theophylline [89], (+)-Cryptocaryone [90], and mela…”
BackgroundOcaña, M. C., Martı́nez-Poveda, B., Marí‐Beffa, M., Quesada, A. R., & Medina, M. Á. (2020) · Scientific Reports · doi:10.1038/s41598-020-63232-z · Cited by 38
Tilekar, K. N., Upadhyay, N., Hess, J. D., Macias, L. G.-F., Mrówka, P., Aguilera, R. J., Meyer‐Almes, F., Iancu, C. V., Choe, J., & Ramaa, C. S. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112603 · Cited by 38
Cheng, Y., Diao, D., Zhang, H., Guo, Q., Wu, X., Song, Y., & Dang, C. (2013) · Biomedical Reports · doi:10.3892/br.2013.211 · Cited by 36
Inhibition of LDHA Deliver Potential Anticancer Performance in Renal Cell Carcinoma
Wang, X., Xu, L., Wu, Q., Liu, M., Tang, F., Cai, Y., Fan, W., Huang, H., & Gu, X. (2017) · Urologia Internationalis · doi:10.1159/000445125 · Cited by 36
Yakisich, J. S., Azad, N., Kaushik, V., & Iyer, A. K. V. (2019) · Stem Cells International · doi:10.1155/2019/6254269 · Cited by 36
Therapeutic implications of glucose transporters (GLUT) in cerebral ischemia
Sharma, V., Singh, T. G., & Mannan, A. (2022) · Neurochemical Research · doi:10.1007/s11064-022-03620-1 · Cited by 36 · cited 5×
“TDZD-8, a small molecule metamorphic inhibitor, has been found to specifically target the Cys289 site of ALDOA, inhibit the glycolytic function of ALDOA, and reduce the stability of HIF-1α to exert anticancer effects [263].”
BackgroundInfluentialJannat, T., Hossain, M. J., El‐Shehawi, A. M., Kuddus, M. R., Rashid, M. A., Albogami, S. M., Jafri, I., El‐Shazly, M., & Haque, M. R. (2022) · Molecules · doi:10.3390/molecules27134024 · Cited by 36
Methyljasmonate displays in vitro and in vivo activity against multiple myeloma cells
Klippel, S., Jakubíková, J., Delmore, J. E., Ooi, M. G. M., McMillin, D. W., Kastritis, E., Laubach, J. P., Richardson, P. G. G., Anderson, K. C., & Mitsiades, C. S. (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2012.09253.x · Cited by 35
Ojeda, P. G., Pérez, A., Ojeda, L., Vargas‐Uribe, M., Rivas, C. I., Salas, M., Vera, J. C., & Reyes, A. M. (2012) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00145.2012 · Cited by 35 · cited 1×
“In addition, natural products such as trehalose (Figure 3K) [78], silibinin (Figure 3L) [79], curcumin (Figure 3M) [80], resveratrol (Figure 3N) [81], naringenin [82], quercetin [83], isoquercetin [84], kaempferol [85], xanthohumol [86], caffeine [87], bezielle [88], theophylline [89], (+)-Cryptocaryone [90], and mela…”
BackgroundCaffeine inhibits glucose transport by binding at the GLUT1 nucleotide-binding site
Sage, J. M., Cura, A. J., Lloyd, K. P., & Carruthers, A. (2015) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00001.2015 · Cited by 35 · cited 1×
“In addition, natural products such as trehalose (Figure 3K) [78], silibinin (Figure 3L) [79], curcumin (Figure 3M) [80], resveratrol (Figure 3N) [81], naringenin [82], quercetin [83], isoquercetin [84], kaempferol [85], xanthohumol [86], caffeine [87], bezielle [88], theophylline [89], (+)-Cryptocaryone [90], and mela…”
BackgroundKim, D. J., Park, Y. S., Kim, N. D., Min, S. H., You, Y.-M., Jung, Y., Koo, H., Noh, H., Kim, J., Park, K. C., et al. (2015) · Molecules and Cells · doi:10.14348/molcells.2015.2314 · Cited by 35
Bao, Y.-Y., Zhong, J.-T., Shen, L.-F., Dai, L.-B., Zhou, S.-H., Fan, J., Yao, H.-T., & Lu, Z.-J. (2022) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17303 · Cited by 35
Epidoxorubicin and lonidamine in refractory or recurrent epithelial ovarian cancer
Gadducci, A., Brunetti, I. M., Muttini, M. P., FANUCCHI, A., Dargenio, F., Giannessi, P. G., & Conte, P. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)00231-s · Cited by 34
de Marinis, F., Rinaldi, M., Ardizzoni, A., Bruzzi, P., Pennucci, M. C., Portalone, L., DʼAprile, M., Ripanti, P., Romano, F., Belli, M., et al. (1999) · Tumori Journal · doi:10.1177/030089169908500306 · Cited by 34
GLUT1 production in cancer cells: a tragedy of the commons
Bukkuri, A., Gatenby, R. A., & Brown, J. S. (2022) · npj Systems Biology and Applications · doi:10.1038/s41540-022-00229-6 · Cited by 34 · cited 1×
“In most cancers, a hypoxic TME induces high expression of GLUT1, which enhances the glucose uptake of cancer cells [34].”
BackgroundGao, X., & Han, H. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26742 · Cited by 33
Cao, X., Jia, G., Zhang, T., Yang, M., Wang, B., Wassenaar, P. A., Cheng, H., Knopp, M. V., & Sun, D. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0688-8 · Cited by 32
Lena, M. D., Lorusso, V., Bottalico, C., Brandi, M., Mitrio, A. D., Catino, A., Guida, M., Latorre, A. C., Leone, B. A., Vallejo, C. T., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.10.3208 · Cited by 32
Targeting PFKFB3 sensitizes chronic myelogenous leukemia cells to tyrosine kinase inhibitor
Zhu, Y., Lu, L., Qiao, C., Shan, Y., Li, H., Qian, S., Hong, M., Zhao, H., Li, J., Yang, Z., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0157-8 · Cited by 32
Allavena, G., Bello, B. D., Tini, P., Volpi, N., Valacchi, G., Miracco, C., Pirtoli, L., & Maellaro, E. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27838 · Cited by 32 · cited 1×
“In addition, natural products such as trehalose (Figure 3K) [78], silibinin (Figure 3L) [79], curcumin (Figure 3M) [80], resveratrol (Figure 3N) [81], naringenin [82], quercetin [83], isoquercetin [84], kaempferol [85], xanthohumol [86], caffeine [87], bezielle [88], theophylline [89], (+)-Cryptocaryone [90], and mela…”
BackgroundTargeting Cancer Metabolism Breaks Radioresistance by Impairing the Stress Response
Schwab, M., Thunborg, K., Azimzadeh, O., von Toerne, C., Werner, C., Shevtsov, M. A., Genio, T. D., Ždralević, M., Pouysségur, J., Renner, K., et al. (2021) · Cancers · doi:10.3390/cancers13153762 · Cited by 32
Genotyping analysis and 18FDG uptake in breast cancer patients: a preliminary research
Bravatà, V., Stefano, A., Cammarata, F. P., Minafra, L., Russo, G. I., Nicolosi, S., Pulizzi, S., Gelfi, C., Gilardi, M. C., & Messa, C. (2013) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-32-23 · Cited by 31
Anticancer activities of vitamin K3 analogues
Wellington, K. W., Hlatshwayo, V., Kolesnikova, N. I., Saha, S. T., Kaur, M., & Motadi, L. R. (2019) · Investigational New Drugs · doi:10.1007/s10637-019-00855-8 · Cited by 30
Ji, Z., Huo, C., & Yang, P. (2020) · International Urology and Nephrology · doi:10.1007/s11255-019-02372-2 · Cited by 30 · cited 2×
“[69] demonstrated that genistein (Figure 3H) could induce apoptosis and inhibit the proliferation of renal cancer cells by increasing ti l tr sf r s .”
BackgroundMitochondrial targeting nano-curcumin for attenuation on PKM2 and FASN
Yang, R., Fang, X.-L., Zhen, Q., Chen, Q., & Feng, C. (2019) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2019.110405 · Cited by 27
Li, H., Hu, S., Pang, Y., Li, M., Chen, L., Liu, F., Liu, M., Wang, Z., & Cheng, X. (2018) · Europe PMC (PubMed Central) · Cited by 27
Li, J., Zhao, M. F., Xu, Y., Hu, X., Dai, Y., & Wang, D. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120310 · Cited by 27
Preparation and release studies of alkannin-containing microcapsules
Assimopoulou, A. N., & Papageorgiou, V. P. (2004) · Journal of Microencapsulation · doi:10.1080/02652040310001637839 · Cited by 26
Sterically stabilized liposomes as a potent carrier for shikonin
Kontogiannopoulos, K. N., Tsermentseli, S. K., Assimopoulou, A. N., & Papageorgiou, V. P. (2014) · Journal of Liposome Research · doi:10.3109/08982104.2014.891233 · Cited by 26
Li, R., Fan, X., Shi, D., Zhu, G., Wang, Y., Luo, L., Pan, H., Yao, X., Leung, E. L., & Liu, L. (2018) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13354 · Cited by 26
Synthesis of Indomorphan Pseudo‐Natural Product Inhibitors of Glucose Transporters GLUT‐1 and ‐3
Ceballos, J., Schwalfenberg, M., Karageorgis, G., Reckzeh, E. S., Sievers, S., Ostermann, C., Pahl, A., Sellstedt, M., Nowacki, J., Corrales, M. A. C., et al. (2019) · Angewandte Chemie · doi:10.1002/ange.201909518 · Cited by 26
Muley, P., Olinger, A., & Tummala, H. (2015) · Nutrition and Cancer · doi:10.1080/01635581.2015.1002626 · Cited by 25
Son, J. Y., Yoon, S., Tae, I. H., Park, Y. J., De, U., Jeon, Y., Park, Y. J., Rhyu, I. J., Lee, B. M., Chung, K., et al. (2018) · Cancer Medicine · doi:10.1002/cam4.1748 · Cited by 25
Correia‐Branco, A., Azevedo, C., Araújo, J. R., Guimarães, J. T., Faria, A., Keating, E., & Martel, F. (2015) · Molecular Human Reproduction · doi:10.1093/molehr/gav043 · Cited by 24 · cited 1×
“In addition, natural products such as trehalose (Figure 3K) [78], silibinin (Figure 3L) [79], curcumin (Figure 3M) [80], resveratrol (Figure 3N) [81], naringenin [82], quercetin [83], isoquercetin [84], kaempferol [85], xanthohumol [86], caffeine [87], bezielle [88], theophylline [89], (+)-Cryptocaryone [90], and mela…”
BackgroundFive decades of doxycycline: Does nanotechnology improve its properties?
Feitosa, R. C., Ishikawa, E. S. A., Alves-Silva, M. F., da Silva-Júnior, A. A., & Nascimento, L. D. O. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.121655 · Cited by 20
Determinants of Ligand Binding Affinity and Cooperativity at the GLUT1 Endofacial Site
Robichaud, T. K., Appleyard, A. N., Herbert, R. B., Henderson, P. J. F., & Carruthers, A. (2011) · Biochemistry · doi:10.1021/bi1020327 · Cited by 18 · cited 1×
“Cytochalasin B (Figure 3A), a cell-permeable mycotoxin, was the first molecule identified to inhibit GLUT1, which reduces glucose uptake in hepatocellular carcinoma cells [41].”
BackgroundThe Cytotoxic Properties of Baeckea frutescens Branches Extracts in Eliminating Breast Cancer Cells
Shahruzaman, S. H., Mustafa, M. F., Ramli, S., Maniam, S., Fakurazi, S., & Maniam, S. (2019) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2019/9607590 · Cited by 17 · cited 1×
“inhibit tumor growth by reducing glucose uptake in breast cancer cells, but there was no obvious cytotoxic effect on normal cells [92].”
BackgroundLigand-based design of GLUT inhibitors as potential antitumor agents
Almahmoud, S. A., Jin, W., Geng, L., Wang, J., Wang, X., Vennerstrom, J. L., & Zhong, H. A. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115395 · Cited by 17
Recent developments in ligands and chemical probes targeting solute carrier transporters
Casiraghi, A., Bensimon, A., & Superti‐Furga, G. (2021) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2021.01.012 · Cited by 16 · cited 2×
“With the advancement of technology, novel GLUT inhibitors, such as PUG-1 (Figure 3E) [54], chromopynones (Figure 3F) [55–57], rapaglutin A [35,58], EF24 [59], ketoximes [36], polyphenolic”
BackgroundChoi, J., Mathew, S., Oerter, S., Appelt‐Menzel, A., Hansmann, J., & Schmitz, T. (2022) · Bioengineering · doi:10.3390/bioengineering9010039 · Cited by 16
Bridging Cancer Biology with the Clinic: Comprehending and Exploiting IDH Gene Mutations in Gliomas
Romanidou, O., Kotoula, V., & Fountzilas, G. (2018) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20101 · Cited by 15
Huang, B., Cai, W., Wang, Q., Liu, F., Xu, M., & Zhang, Y. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/9480316 · Cited by 15
Self-citationComputer‐aided identification of a novel pyruvate kinase M2 activator compound
Li, Y., Bao, M., Yang, C., Chen, J., Zhou, S. W., Sun, R., Wu, C., Li, X., & Bao, J. (2018) · Cell Proliferation · doi:10.1111/cpr.12509 · Cited by 14
Tomoda, A. (2011) · Oncology Reports · doi:10.3892/or.2011.1531 · Cited by 12
Design, Synthesis, and Evaluation of GLUT Inhibitors
Granchi, C., Tuccinardi, T., & Minutolo, F. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7507-5_8 · Cited by 11 · cited 3×
“esters [60], pyrazolo-pyrimidines [37], quinazolines [61], phenylalanine amides [62] and many more [35,58,63–67], EF24 [59], ketoximes [36], polyphenolic esters [60], pyrazolopyrimidines [37], quinazolines [61], phenylalanine amides [62], and many more [63–67], have emerged but need to be more deeply investigated.”
BackgroundGao, C., Hou, G., Liu, J., Ru, T., Xu, Y., Zhao, S., Ye, H., Zhang, L., Chen, K., Guo, Y., et al. (2019) · Angewandte Chemie · doi:10.1002/ange.201912489 · Cited by 11
Huang, Y., & Chang, N.-W. (2017) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12774 · Cited by 9
Volland, J. M., Kaupp, J., Schmitz, W., Wünsch, A. C., Balint, J., Möllmann, M., El‐Mesery, M., Frackmann, K., Peter, L., Hartmann, S., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169220 · Cited by 9
Chang, S. M., & Heiden, M. G. V. (2022) · Cell chemical biology · doi:10.1016/j.chembiol.2022.03.004 · Cited by 7 · cited 2×
“The GLUT family has 14 members, all of which are capable of selectively transporting different sugar molecules [28].”
BackgroundDiscovery of a Potent GLUT Inhibitor from a Library of Rapafucins by Using 3D Microarrays
Guo, Z., Cheng, Z., Wang, J., Liu, W., Peng, H., Wang, Y., Rao, A., Li, R., Ying, X., Korangath, P. C., et al. (2019) · Angewandte Chemie · doi:10.1002/ange.201905578 · Cited by 7 · cited 2×
“With the advancement of technology, novel GLUT inhibitors, such as PUG-1 (Figure 3E) [54], chromopynones (Figure 3F) [55–57], rapaglutin A [35,58], EF24 [59], ketoximes [36], polyphenolic”
Abstract 557: Taking the sweet out of Th17 cells to potentiate immuno-oncology drugs
Telang, S., Yaddanadupi, K., Tapolsky, G. H., Redman, R. A., & Chesney, J. A. (2016) · Cancer Research · doi:10.1158/1538-7445.am2016-557 · Cited by 3
Cited by
Altered metabolism in cancer: insights into energy pathways and therapeutic targets
Tufail, M., Jiang, C.-H., & Li, N. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02119-3 · Cited by 534
“By inhibiting glucose transporters, specifically GLUT1, which is often overexpressed in various cancers, these inhibitors effectively starve cancer cells of their primary energy source [60, 216].”
BackgroundUnveiling the mechanisms and challenges of cancer drug resistance
Khan, S. U., Fatima, K., Aisha, S., & Malik, F. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-023-01302-1 · Cited by 417
“Further reports suggest the resistance dependence of cancer cells on glycolytic intermediate and glucose transporter are therapeutically significant nodes in both preclinical and clinical settings [292].”
BackgroundModulating Glycolysis to Improve Cancer Therapy
Chelakkot, C., Chelakkot, V. S., Shin, Y., & Song, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032606 · Cited by 374
“Additionally, several of the glycolysis inhibitors that have been developed for clinical use have been shown to have off-target effects, killing non-cancerous cells [327].”
BackgroundWang, Z., Zhang, X., Fang, C., Liu, X., Liao, Q., Wu, N., & Wang, J. (2024) · Immunology · doi:10.1111/imm.13793 · Cited by 204
“As a result, inhibiting glucose metabolism enzymes has shown great promise as a novel cancer treatment strategy [140 – 142].”
Lu, H., Tong, W., Jiang, M., Liu, H., Meng, C., Wang, K., & Mu, X. (2024) · ACS Nano · doi:10.1021/acsnano.4c04024 · Cited by 105
Metadata
- Authors
- Zhang, Y., Li, Q., Huang, Z., Li, B., Nice, E. C., Huang, C., Wei, L., & Zou, B.
- Affiliations
- Sichuan University (CN)
- Monash University (AU)
- Weifang Medical University (CN)
- Corresponding author
- Wei, Liuya
- Zou, Bingwen
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2022-09-21
- Volume
- 14
- Issue
- 19
- Pages
- 4568
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC9559313
- OpenAlex
- W4296991129
- Cited by
- 144
- References
- 322
- Citations by year
- 2026: 21 · 2025: 54 · 2024: 40 · 2023: 28 · 2022: 1
- FWCI
- 3.71
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Clinical Research Incubation Project, West China Hospital, Sichuan University (2021HXFH022, 22GJHZ0015, YXJL-2021-1009-0660, ZYGD22007, 82130082)
- Science and Technology Department of Sichuan Province (2021HXFH022, 22GJHZ0015, YXJL-2021-1009-0660, ZYGD22007, 82130082)
- Beijing Medical Award Foundation (2021HXFH022, 22GJHZ0015, YXJL-2021-1009-0660, ZYGD22007, 82130082)
- 1·3·5 project for disciplines of excellence (2021HXFH022, 22GJHZ0015, YXJL-2021-1009-0660, ZYGD22007, 82130082)
- National Natural Science Foundation of China (2021HXFH022, 22GJHZ0015, YXJL-2021-1009-0660, ZYGD22007, 82130082)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- glucose metabolism reprogramming, glucose metabolism enzymes, cancer metabolism, anticancer drug development, metabolic therapy, natural products, small molecule modulators, combination therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.